Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
By Takashi Ebisawa After a major setback in an I/O combo trial last year, AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) notched up approval as a single-agent maintenance treatment for a previously untapped pool of Stage III lung cancer patients. Japan…
To read the full story
Related Article
- I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
October 5, 2018
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
September 13, 2018
- I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
September 5, 2018
- I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
August 28, 2018
- I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…